

## ASX ANNOUNCEMENT

### PeriCoach® granted patent protection in China

**3 August 2016: Brisbane, Australia** – Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System has been granted patent protection (Patent N° ZL201280018210.2) in the People’s Republic of China for the device’s unique pelvic floor force sensing technology. It is estimated that there are nearly 227 million target women with urinary incontinence in China. This is the first of the PeriCoach patents to be granted in the major markets and is in line with the overall strategy for PeriCoach: to secure intellectual property protection for key geographies that have ageing populations, with increased awareness of urinary incontinence, and growing demand towards conservative treatment solutions.

It has remained a top priority to ensure the PeriCoach becomes a global product, therefore Analytica has maintained its investment in intellectual protection in major markets around the world.

Analytica CEO Geoff Daly said – “Patent protection is critical in licencing negotiations as it affords the licencing partner freedom to operate in the market. China and other emerging markets are a major part of our global strategy for the PeriCoach system. Securing these markets is of significant value to future partners.”

Analytica also has PeriCoach patents pending in the US, India, Brazil, Australia, Europe and Japan. Many of these jurisdictions allow patent protection 20 years from the original lodgement date providing patent coverage to 2032.

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



#### About Analytica Limited

Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.

